ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
Gennex Laboratories will hold a board meeting on November 14, 2026. The board will consider unaudited financial results for the quarter ended September 30, 2026.
Gennex Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Gennex Laboratories announced the appointment of Mr. Dipankar Dasgupta as Independent Director, replacing Mr. Amudala Sreeramulu Nageswar Rao, effective October 1, 2026.
Gennex Laboratories Limited held its 41st electronic Annual General Meeting on September 30, 2026. Proceedings included the adoption of financial statements and appointment of company directors.
Subsidiary Deccan Remedies Ltd received approvals from the Drug Control Administration, Andhra Pradesh, to manufacture ten additional pharmaceutical products and test licences at its facility.
Gennex Laboratories Limited announced the closure of its register of members from September 23 to September 30, 2026. This is for the upcoming 41st Annual General Meeting.
Gennex Laboratories announced the outcome of its board meeting, approving the draft directors' report and scheduling the 41st Annual General Meeting for September 30, 2026.
Gennex Laboratories has announced a board meeting scheduled for September 4, 2026, to discuss the upcoming 41st Annual General Meeting and other business matters.
Gennex Laboratories Ltd reported revenue from operations of ₹39.8 Cr (+16.4% YoY) and net profit of ₹4.7 Cr (-6.0% YoY) for Q1 FY27.